Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Mast Therapeutics (NASDAQ:SVRA) Share Price

News coverage about Mast Therapeutics (NASDAQ:SVRA) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mast Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.7798109020113 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several analysts recently commented on the stock. Canaccord Genuity restated a “buy” rating and set a $18.00 price target on shares of Mast Therapeutics in a report on Monday, July 17th. Zacks Investment Research upgraded shares of Mast Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a report on Wednesday.

Mast Therapeutics (NASDAQ:SVRA) traded down 1.26% during mid-day trading on Friday, hitting $5.50. 20,595 shares of the company traded hands. The company’s 50-day moving average price is $6.10 and its 200 day moving average price is $5.93. Mast Therapeutics has a one year low of $4.60 and a one year high of $9.88. The company’s market capitalization is $75.94 million.

In other news, insider Jaakko Taneli Jouhikainen purchased 10,500 shares of Mast Therapeutics stock in a transaction on Wednesday, June 7th. The stock was purchased at an average price of $4.75 per share, with a total value of $49,875.00. Following the transaction, the insider now directly owns 235,326 shares in the company, valued at approximately $1,117,798.50. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Joseph S. Mccracken purchased 52,250 shares of Mast Therapeutics stock in a transaction on Wednesday, June 7th. The shares were purchased at an average cost of $4.75 per share, with a total value of $248,187.50. Following the transaction, the director now owns 59,866 shares in the company, valued at $284,363.50. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 64,850 shares of company stock valued at $308,038. 4.26% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Mast Therapeutics (NASDAQ:SVRA) Share Price” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mast-therapeutics-nasdaqsvra-share-price-updated.html.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

What are top analysts saying about Mast Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mast Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit